Venous thromboembolism is a common complication of patients with hematologic malignancies, due both to release of procoagulant factors by tumor cells and to external factors, such us drugs. In multiple myeloma patients, the risk is increased by use of immunomodulants, especially when associated to multidrug therapy, during the induction phase. Prevention of venous thromboembolism in myeloma patients is highly recommended but specific guidelines are still lacking. The most common approach is to stratify the thrombotic risk according to individual, myeloma-related and therapy-related risk factors and to use aspirin for all patients, except those with two or more thrombotic risk factors who should be treated with traditional oral or parenteral anticoagulant. A more controversial approach indicates for prophylaxis either anticoagulant or aspirin, regardless of risk stratification. Recent trials investigate prophylaxis in myeloma patients with direct oral anticoagulants, based on studies showing efficacy and safety of this new class of drugs in the treatment and prophylaxis of thrombosis in patients with any malignancy. The results of these trials are encouraging but they need to be confirmed by larger studies. An international consensus about best prophylaxis to prevent venous thromboembolism in patients with multiple myeloma on treatment is still missing. Therefore, thrombosis in multiple myeloma remains an ongoing issue.

Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going? / Lapietra, G.; Serrao, A.; Fazio, F.; Petrucci, M. T.; Chistolini, A.. - In: JOURNAL OF THROMBOSIS AND THROMBOLYSIS. - ISSN 0929-5305. - 52:(2021), pp. 584-589. [10.1007/s11239-020-02354-7]

Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?

Lapietra G.;Serrao A.;Fazio F.;Petrucci M. T.;Chistolini A.
2021

Abstract

Venous thromboembolism is a common complication of patients with hematologic malignancies, due both to release of procoagulant factors by tumor cells and to external factors, such us drugs. In multiple myeloma patients, the risk is increased by use of immunomodulants, especially when associated to multidrug therapy, during the induction phase. Prevention of venous thromboembolism in myeloma patients is highly recommended but specific guidelines are still lacking. The most common approach is to stratify the thrombotic risk according to individual, myeloma-related and therapy-related risk factors and to use aspirin for all patients, except those with two or more thrombotic risk factors who should be treated with traditional oral or parenteral anticoagulant. A more controversial approach indicates for prophylaxis either anticoagulant or aspirin, regardless of risk stratification. Recent trials investigate prophylaxis in myeloma patients with direct oral anticoagulants, based on studies showing efficacy and safety of this new class of drugs in the treatment and prophylaxis of thrombosis in patients with any malignancy. The results of these trials are encouraging but they need to be confirmed by larger studies. An international consensus about best prophylaxis to prevent venous thromboembolism in patients with multiple myeloma on treatment is still missing. Therefore, thrombosis in multiple myeloma remains an ongoing issue.
2021
direct oral anticoagulants; multiple myeloma; prophylaxis; venous thromboembolism
01 Pubblicazione su rivista::01a Articolo in rivista
Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going? / Lapietra, G.; Serrao, A.; Fazio, F.; Petrucci, M. T.; Chistolini, A.. - In: JOURNAL OF THROMBOSIS AND THROMBOLYSIS. - ISSN 0929-5305. - 52:(2021), pp. 584-589. [10.1007/s11239-020-02354-7]
File allegati a questo prodotto
File Dimensione Formato  
Lapietra_Venous-thromboembolism_2021.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 572.82 kB
Formato Adobe PDF
572.82 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1475196
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact